Fixell Biotech AB is a KTH (the Royal Institute of Technology, Sweden) spin-off that transform technological advancement developed from state-of-the art research to address bioprocess challenges in Cell and Gene Therapy (CGT). We specialize in advanced bioprocess development, dedicated to driving innovation, enhancing productivity, and delivering superior results for our clients in the life sciences sector.
Fixell Biotech AB is a leading provider of research and development services in the life sciences sector. Our team of experts provides tailored solutions to meet the needs of both academic and commercial enterprises, delivering high-quality results with a focus on innovation, efficiency, and regulatory compliance.